Disrupted hypothalamic transcriptomics and proteomics in a mouse model of type 2 diabetes exposed to recurrent

Judit Castillo-Armengol1,2, Flavia Marzetta3, Ana Rodriguez Sanchez-Archidona2

  • 1Novo Nordisk A/S, Måløv, Denmark.

Diabetologia
|November 28, 2023
PubMed
Abstract

Insights

Repeated hypoglycemia impairs the counterregulatory response in diabetes. This study reveals molecular defects in the hypothalamus, affecting neuronal signaling and glucose sensing, with features of neurodegeneration.

Area of Science:

  • Neuroscience
  • Endocrinology
  • Molecular Biology

Background:

  • Repeated insulin-induced hypoglycemia progressively impairs the counterregulatory response (CRR) in diabetes.
  • This defect involves reduced glucagon and counterregulatory hormone secretion.
  • Glucose-responsive hypothalamic neurons orchestrate the CRR.

Purpose of the Study:

  • To identify hypothalamic gene and protein expression changes underlying impaired CRR in a mouse model.
  • To investigate molecular adaptations in the hypothalamus following recurrent hypoglycemia.

Main Methods:

  • Mice were exposed to acute (AH) or recurrent (RH) hypoglycemia.
  • Hypothalamic and cortical single-nuclei RNA sequencing (snRNA-seq) and synaptosomal proteomic analysis were performed.
  • Plasma glucagon levels were measured.

Main Results:

  • Recurrent hypoglycemia (RH) significantly reduced glucagon secretion compared to acute hypoglycemia (AH).
  • Transcriptomic analysis revealed altered gene expression in hypothalamic neurons, oligodendrocytes, and astrocytes in RH mice.
  • Key changes included decreased expression of oxidative phosphorylation genes, reduced neurotransmitter scavenging capacity, and increased amyloid-beta production, with distinct cortical adaptations.

Conclusions:

  • Recurrent hypoglycemia induces widespread hypothalamic defects affecting neuronal signaling and glucose sensing, mimicking neurodegenerative features.
  • These molecular changes contribute to impaired counterregulation in a mouse model of type 2 diabetes.
  • Hypothalamic adaptations to recurrent hypoglycemia differ from those in the cortex.

Related Concept Videos

Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
950
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
272